

Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Apr-2023
Document Type: USP Monographs
DocId: GUID-4C66129F-7AE4-4ED7-B631-834E40397D56_4_en-US
DOI: https://doi.org/10.31003/USPNF_M5190_04_01
DOI Ref: 3n611

© 2025 USPC
Do not distribute

Anticoagulant Heparin Solution

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click www.uspnf.com/rb-anticoagulant-heparin-sol-20230331.

DEFINITION

Anticoagulant Heparin Solution is a sterile solution of Heparin Sodium in Sodium Chloride Injection. Its potency is NLT 90.0% and NMT 110.0% of the potency stated on the label in terms of USP Heparin Units. It contains NLT 0.85% and NMT 0.95% of [sodium chloride](#) (NaCl). It may be buffered. It contains no antimicrobial agents.

Prepare Anticoagulant Heparin Solution as follows.

| | |
|--|--------------|
| Heparin Sodium | 75,000 Units |
| Sodium Chloride Injection, sufficient quantity to make | 1000 mL |

Add the Heparin Sodium, in solid form or in solution, to the Sodium Chloride Injection, mix, filter if necessary, and sterilize.

ASSAY

• ANTI-FACTOR IIa POTENCY

pH 8.4 buffer: Dissolve 6.10 g of [tris\(hydroxymeth yl\)aminomethane](#), 10.20 g of [sodium chloride](#), 2.80 g of [edetate sodium](#), and, if suitable, between 0 and 10.00 g of [polyethylene glycol 6000](#) and/or 2.00 g of [bovine serum albumin](#) in 800 mL of [water](#). [NOTE—2.00 g of [human albumin](#) may be substituted for 2.00 g of [bovine serum albumin](#).] Adjust with [hydrochloric acid](#) to a pH of 8.4, and dilute with [water](#) to 1000 mL.

Antithrombin solution: Reconstitute a vial of antithrombin (see [Reagents, Indicators, and Solutions—Reagent Specifications](#)) in [water](#) to obtain a solution of 5 Antithrombin IU/mL. Dilute this solution with *pH 8.4 buffer* to obtain a solution having a concentration of 0.125 Antithrombin IU/mL.

Thrombin human solution: Reconstitute thrombin human (factor IIa) (see [Reagents, Indicators, and Solutions—Reagent Specifications](#)) in [water](#) to give 20 Thrombin IU/mL, and dilute with *pH 8.4 buffer* to obtain a solution having a concentration of 5 Thrombin IU/mL. [NOTE—The thrombin should have a specific activity of NLT 750 IU/mg.]

Chromogenic substrate solution: Prepare a solution of a suitable chromogenic thrombin substrate for amidolytic test (see [Reagents, Indicators, and Solutions—Reagent Specifications](#)) in water to obtain a concentration of 1.25 mM.

Stopping solution: 20% (v/v) solution of [acetic acid](#)

Standard solutions: Reconstitute the entire contents of an ampule of [USP Heparin Sodium for Assays RS](#) with [water](#), and dilute with *pH 8.4 buffer* to obtain at least four dilutions in the concentration range between 0.005 and 0.03 USP Heparin Unit/mL.

Sample solutions: Proceed as directed for *Standard solutions* to obtain concentrations of Anticoagulant Heparin Solution similar to those obtained for the *Standard solutions*.

Analysis

[NOTE—The procedure can also be performed using alternative platforms.]

For each dilution of the *Standard solutions* and the *Sample solutions*, at least duplicate samples should be tested. Label a suitable number of tubes, depending on the number of replicates to be tested. For example, if five blanks are to be used: B1, B2, B3, B4, and B5 for the blanks; T1, T2, T3, and T4 each at least in duplicate for the dilutions of the *Sample solutions*; and S1, S2, S3, and S4 each at least in duplicate for the dilutions of the *Standard solutions*. Distribute the blanks over the series in such a way that they accurately represent the behavior of the reagents during the experiments. [NOTE—Treat the tubes in the order B1, S1, S2, S3, S4, B2, T1, T2, T3, T4, B3, T1, T2, T3, T4, B4, S1, S2, S3, S4, B5.] Note that after each addition of a reagent, the incubation mixture should be mixed without allowing bubbles to form. Add twice the volume (100–200 µL) of *Antithrombin solution* to each tube containing one volume (50–100 µL) of either the *pH 8.4 buffer* or an appropriate dilution of the *Standard solutions* or the *Sample solutions*. Mix, but do not allow bubbles to form. Incubate at 37°

for at least 1 min. Add to each tube 25–50 µL of *Thrombin human solution*, and incubate for at least 1 min. Add 50–100 µL of *Chromogenic substrate solution*. Please note that all reagents, *Standard solutions*, and *Sample solutions* should be prewarmed to 37° just before use. Two different types of measurements can be recorded:

1. Endpoint measurement: Stop the reaction after at least 1 min with 50–100 µL of *Stopping solution*. Measure the absorbance of each solution at 405 nm using a suitable spectrophotometer (see [Ultraviolet-Visible Spectroscopy \(857\)](#)). The RSD over the blank readings is less than 10%.
2. Kinetic measurement: Follow the change in absorbance for each solution over 1 min at 405 nm using a suitable spectrophotometer (see [Ultraviolet-Visible Spectroscopy \(857\)](#)). Calculate the change in absorbance/min ($\Delta OD/\text{min}$). The blanks for kinetic measurement are also expressed as $\Delta OD/\text{min}$ and should give the highest values because they are carried out in the absence of heparin. The RSD over the blank readings is less than 10%.

Calculations: The statistical models for *Slope ratio assay* or *Parallel-line assay* can be used, depending on which model best describes the correlation between concentration and response.

Parallel-line assay: For each series, calculate the regression of the absorbance or change in absorbance/min against log concentrations of the *Standard solutions* and the *Sample solutions*, and calculate the potency of Anticoagulant Heparin Solution in USP Units/mL using statistical methods for parallel-line assays.

Slope ratio assay: For each series, calculate the regression of the log absorbance or the log change in absorbance/min against concentrations of the *Standard solutions* and the *Sample solutions*, and calculate the potency of Anticoagulant Heparin Solution in USP Units/mL using statistical methods for slope ratio assays.

Acceptance criteria: 90.0%–110.0% of the potency stated on the label in terms of USP Heparin Units.

• **SODIUM CHLORIDE**

Sample solution: Solution and [potassium chromate TS](#) (5:1)

Analysis: Titrate with [0.1 N silver nitrate VS](#). Each mL of [0.1 N silver nitrate VS](#) is equivalent to 5.844 mg of [NaCl](#).

SPECIFIC TESTS

- [pH \(791\)](#): Between 5.0 and 7.5
- [BACTERIAL ENDOTOXINS TEST \(85\)](#): It contains NMT 2.5 USP Endotoxin Units/mL.
- [INJECTIONS AND IMPLANTED DRUG PRODUCTS \(1\)](#): Meets the requirements

ADDITIONAL REQUIREMENTS

Change to read:

- **PACKAGING AND STORAGE:** Preserve in single-dose containers, of colorless, transparent, ▲preferably▲ (RB 1-Apr-2023) Type I or Type II glass, or of a suitable plastic material (see [Medical Devices—Bacterial Endotoxin and Pyrogen Tests \(161\)](#)).
- **LABELING:** Label it in terms of USP Heparin Units, and to indicate the number of mL of Solution required per 100 mL of whole blood.
- **USP REFERENCE STANDARDS (11)**
[USP Heparin Sodium for Assays RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|--------------------------------|--|--|
| ANTICOAGULANT HEPARIN SOLUTION | Rebecca C. Potts Associate Scientific Liaison | BIO32020 Biologics Monographs 3 - Complex Biologics and Vaccines |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-4C66129F-7AE4-4ED7-B631-834E40397D56_4_en-US

DOI: https://doi.org/10.31003/USPNF_M5190_04_01

DOI ref: [3n61l](#)